Tag Archives: aspirin

High-on-Aspirin Residual Platelet Reactivity Evaluated Using the Multiplate® Point-of-Care Device

Mărginean Alina1,2*, Moldovan Valeriu1, Mărginean Mihai1,2

1 University of Medicine and Pharmacy of Tîrgu Mures, Romania
2 Emergency Military Hospital “Dr. Constantin Papilian” Cluj-Napoca, Romania

DOI: 10.1515/amma-2015-0124

Objective: The aim of this study was to evaluate the prevalence of aspirin non-responsiveness using whole blood multiple electrode aggregometry and to investigate the role of different clinical and laboratory variables associated with the lack of response.
Methods: The present study included 116 aspirin treated patients presented with acute coronary syndromes or stroke. Response to aspirin was assessed by impedance aggregometry using arachidonic acid as agonist, in a final concentration of 0.5 mM (ASPI test).
Results: In our data set 81% (n=94) were responders and 19% (n=22) non-responders showing high-on-aspirin platelet reactivity. Correlation analysis showed that the ward of admittance, low-density lipoproteins (LDL), concomitant antibiotic treatment, beta-adrenergic receptor blockers, history of myocardial infarction as well as PCI performed on Cardiology patients have different degrees of association with aspirin response.
Conclusion: Concomitant treatment with beta-adrenergic receptor inhibitors, history of myocardial infarction and Cardiology ward admittance significantly increased the chance of responding to aspirin treatment whereas antibiotic therapy and low-density lipoproteins cholesterol seemed to increase the risk of high-on-aspirin residual platelet reactivity.

Keywords: , , , ,
Full text: PDF

Upper Digestive Mucosal Changes in Patients Taking Low-dose Aspirin

Negovan Anca1, Băţagă Simona2, Sabău M3, Cozlea L1, Ţilea I1, Sárkány Z3

1 3rd Medical Clinic, University of Medicine and Pharmacy, Tîrgu Mureş, Romania
2 Department of Gastroenterology, University of Medicine and Pharmacy, Tîrgu Mureş, Romania
3 Department of Physiology, University of Medicine and Pharmacy, Tîrgu Mureș, Romania

Objective: The benefits of antiplatelet therapies for treatment and prevention of cardiovascular diseases have been demonstrated in the last years, but these therapies increase the risk of mucosal damage in the gastrointestinal tract. We aimed to evaluate endoscopic mucosal lesions in patients not referred for endoscopy, with a new recommendation for long term low-dose aspirin, who have not taken the drug before endoscopy and in patients taking long-term low-dose aspirin.
Material and methods: Two-hundred twenty-five patients who had accepted an endoscopy were included (90 with low-dose aspirin, 135 with recommendation for low-dose aspirin). With few exceptions, there were no statistically significant differences in patient groups regarding social habits, chronic diseases, ulcer history, concomitant drug or digestive symptoms.
Results: Severe Lanza scores were significantly more frequent in patients with low-dose aspirin than in patients without aspirin (60% vs. 30.4%, p<0.01). In patients with chronic low-dose aspirin, H. pylori infection was significantly less frequent than in patients not taking this therapy (38.9% vs. 50.4%, p=0.05), while gastric atrophy and/or intestinal metaplasia were more frequent (48.9% vs. 36.3%, p=0.04). Active infection with H. pylori in taken biopsies was associated with more severe lesions, including ulcers, in both groups, while gastric atrophy and/or intestinal metaplasia were significantly associated with severe endoscopic lesions in patients with low-dose aspirin.
Conclusions: Patients with recommendation for long term treatment with low-dose aspirin frequently present severe mucosal endoscopic lesions and multiple risk factors for gastrointestinal complications before starting the treatment. Patients taking low-dose aspirin on a daily basis present more severe endoscopic lesions when an active H. pylori infection and premalignant histological changes are present.

Keywords: , ,
Full text: PDF